×
About 5,803 results

ALLMedicine™ Calcitonin Gene-related Peptide Center

Research & Reviews  2,733 results

The PLGA nanoparticles for sustainable release of CGRP to ameliorate the inflammatory a...
https://doi.org/10.1080/10717544.2021.1902021
Drug Delivery; Wang F, Deng Y et. al.

May 7th, 2021 - The calcitonin gene-related peptide (CGRP) has been demonstrated relating to vascular and inflammatory regulations not only the nerve systems. As the anti-inflammation factor and the most potent vasodilator, the CGRP holds therapeutic potentials f...

Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered w...
https://doi.org/10.1007/s40261-021-01034-5 10.1146/annurev-physiol-030212-183717 10.1212/01.wnl.0000252808.97649.21 10.1111/head.12878 10.1186/1129-2377-15-2 10.1177/2514183X18823377 10.1111/head.12550 10.1111/j.1468-2982.2008.01819.x 10.1016/S0140-6736(19)32504-8 10.1016/S1474-4422(20)30234-9 10.1002/jcph.1610 10.1016/0006-2952(96)85085-4
Clinical Drug Investigation; Boinpally R, Spaventa J et. al.

May 5th, 2021 - Atogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist in development for preventive treatment of migraine. To evaluate potential pharmacokinetic drug-drug interactions (DDIs), safety and tolerability of atogepant co-admin...

A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in H...
https://doi.org/10.1002/cpdd.940
Clinical Pharmacology in Drug Development; Boinpally R, McNamee B et. al.

May 4th, 2021 - Atogepant is a selective, oral calcitonin gene-related peptide receptor antagonist in development for preventive treatment of migraine. This randomized, double-blind, phase 1 crossover study evaluated the cardiac repolarization effect of a single ...

Esophageal Mucosa Innervation in Children With Nonerosive Reflux Disease.
https://doi.org/10.14309/ajg.0000000000001286
The American Journal of Gastroenterology; Nikaki K, Lee C et. al.

Apr 30th, 2021 - Esophageal mucosa innervation in adults with nonerosive reflux disease (NERD) is more superficial compared with healthy volunteers. We delineated the esophageal mucosal innervation in pediatric NERD and controls. Distal and proximal pediatric esop...

Efficacy of galcanezumab in patients with migraine who did not benefit from commonly pr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063415
BMC Neurology; Kuruppu DK, Tobin J et. al.

Apr 24th, 2021 - Galcanezumab is a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) indicated for the preventive treatment of migraine. While galcanezumab has demonstrated efficacy in patients who did not respond to prior preventive medications in ...

see more →

Guidelines  1 results

European headache federation guideline on the use of monoclonal antibodies acting on th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734227
The Journal of Headache and Pain; Sacco S, Bendtsen L et. al.

Jan 17th, 2019 - Monoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor (erenumab) and thr...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  2,877 results

The PLGA nanoparticles for sustainable release of CGRP to ameliorate the inflammatory a...
https://doi.org/10.1080/10717544.2021.1902021
Drug Delivery; Wang F, Deng Y et. al.

May 7th, 2021 - The calcitonin gene-related peptide (CGRP) has been demonstrated relating to vascular and inflammatory regulations not only the nerve systems. As the anti-inflammation factor and the most potent vasodilator, the CGRP holds therapeutic potentials f...

Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered w...
https://doi.org/10.1007/s40261-021-01034-5 10.1146/annurev-physiol-030212-183717 10.1212/01.wnl.0000252808.97649.21 10.1111/head.12878 10.1186/1129-2377-15-2 10.1177/2514183X18823377 10.1111/head.12550 10.1111/j.1468-2982.2008.01819.x 10.1016/S0140-6736(19)32504-8 10.1016/S1474-4422(20)30234-9 10.1002/jcph.1610 10.1016/0006-2952(96)85085-4
Clinical Drug Investigation; Boinpally R, Spaventa J et. al.

May 5th, 2021 - Atogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist in development for preventive treatment of migraine. To evaluate potential pharmacokinetic drug-drug interactions (DDIs), safety and tolerability of atogepant co-admin...

A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in H...
https://doi.org/10.1002/cpdd.940
Clinical Pharmacology in Drug Development; Boinpally R, McNamee B et. al.

May 4th, 2021 - Atogepant is a selective, oral calcitonin gene-related peptide receptor antagonist in development for preventive treatment of migraine. This randomized, double-blind, phase 1 crossover study evaluated the cardiac repolarization effect of a single ...

Esophageal Mucosa Innervation in Children With Nonerosive Reflux Disease.
https://doi.org/10.14309/ajg.0000000000001286
The American Journal of Gastroenterology; Nikaki K, Lee C et. al.

Apr 30th, 2021 - Esophageal mucosa innervation in adults with nonerosive reflux disease (NERD) is more superficial compared with healthy volunteers. We delineated the esophageal mucosal innervation in pediatric NERD and controls. Distal and proximal pediatric esop...

Efficacy of galcanezumab in patients with migraine who did not benefit from commonly pr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063415
BMC Neurology; Kuruppu DK, Tobin J et. al.

Apr 24th, 2021 - Galcanezumab is a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) indicated for the preventive treatment of migraine. While galcanezumab has demonstrated efficacy in patients who did not respond to prior preventive medications in ...

see more →

News  187 results

Intranasal Third-Generation CGRP Effective for Acute Migraine
https://www.medscape.com/viewarticle/949517

Apr 18th, 2021 - Intranasal zavegepant, a third-generation calcitonin gene-related peptide (CGRP) receptor agonist, is effective and well tolerated in the treatment of acute migraine, new research shows. In a randomized dose-ranging, placebo-controlled, phase 2/3 ...

CGRPs Promising for Prevention of Chronic Cluster Headache
https://www.staging.medscape.com/viewarticle/937760

Sep 20th, 2020 - Treatment with calcitonin gene-related peptide (CGRP) monoclonal antibodies may reduce the frequency of chronic cluster headache (CCH) attacks in patients with an inadequate response to other preventive medications, new research shows. In findings...

CGRPs Promising for Prevention of Chronic Cluster Headache
https://www.medscape.com/viewarticle/937760

Sep 20th, 2020 - Treatment with calcitonin gene-related peptide (CGRP) monoclonal antibodies may reduce the frequency of chronic cluster headache (CCH) attacks in patients with an inadequate response to other preventive medications, new research shows. In findings...

FDA Drug Approvals, Internal Medicine — 2020 Midyear Review
https://reference.staging.medscape.com/viewarticle/935373

Aug 13th, 2020 - Gastroenterology Pizensy (lactitol) Lactitol exerts an osmotic effect, causing an influx of water into the small intestine that results in a laxative effect in the colon. It is indicated for adults with chronic idiopathic constipation . Approval w...

Adding CGRP to Botox Safe, Effective for Migraine Prevention
https://www.medscape.com/viewarticle/932599

Jun 17th, 2020 - Adjunctive preventive therapy with a calcitonin gene-related peptide monoclonal antibody (CGRP-mAb) medication is safe and effective in patients with chronic migraine who have only achieved a partial response to onabotulinumtoxinA (Botox) treatmen...

see more →